Puma Biotechnology - PBYI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 237.55 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.37
▲ +0.05 (2.16%)

This chart shows the closing price for PBYI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Puma Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PBYI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PBYI

Analyst Price Target is $8.00
▲ +237.55% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Puma Biotechnology in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 237.55% upside from the last price of $2.37.

This chart shows the closing price for PBYI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Puma Biotechnology. This rating has held steady since August 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022HC WainwrightLower TargetBuy$12.00 ➝ $8.00Low
7/8/2022HC WainwrightReiterated RatingBuy$12.00N/A
5/6/2022HC WainwrightLower Target$14.00 ➝ $12.00Medium
9/27/2021CitigroupUpgradeNeutral ➝ Buy$11.00High
8/6/2021Royal Bank of CanadaLower TargetSector Perform$13.00 ➝ $6.00High
8/6/2021The Goldman Sachs GroupLower TargetSell$9.00 ➝ $8.00High
5/10/2021HC WainwrightReiterated RatingBuy$15.00High
8/10/2020CitigroupLower TargetNeutral$14.00 ➝ $12.00Medium
8/7/2020SVB LeerinkLower TargetMarket Perform$14.00 ➝ $10.00High
6/25/2020Bank of AmericaInitiated CoverageUnderperform$9.00High
5/20/2020Cantor FitzgeraldBoost TargetNeutral$14.00 ➝ $16.00High
5/15/2020SVB LeerinkReiterated RatingMarket PerformHigh
5/10/2020Royal Bank of CanadaReiterated RatingHold$13.00High
5/1/2020HC WainwrightReiterated RatingBuy$15.00High
4/20/2020Royal Bank of CanadaReiterated RatingHold$13.00High
2/28/2020CowenReiterated RatingHold$17.00High
2/26/2020HC WainwrightReiterated RatingBuy$15.00High
2/4/2020SVB LeerinkReiterated RatingMarket PerformHigh
1/27/2020Royal Bank of CanadaReiterated RatingHold$13.00Low
1/3/2020GuggenheimDowngradeBuy ➝ NeutralLow
12/12/2019HC WainwrightReiterated RatingBuy$15.00Medium
12/6/2019HC WainwrightInitiated CoverageBuy$15.00Medium
11/8/2019Cantor FitzgeraldLower TargetNeutral$20.00 ➝ $14.00High
11/7/2019BarclaysLower TargetUnderweight$9.00 ➝ $6.00High
11/7/2019Royal Bank of CanadaLower TargetSector Perform$13.00High
10/8/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$24.00 ➝ $8.00High
8/12/2019CitigroupSet TargetHold$13.00High
8/12/2019JPMorgan Chase & Co.Reiterated RatingSell$13.00Medium
8/9/2019CowenReiterated RatingHold$25.00Low
8/9/2019BarclaysLower TargetUnderweight$21.00 ➝ $9.00High
7/5/2019CowenReiterated RatingHold$28.00High
6/5/2019CowenSet TargetHold$27.00Medium
5/29/2019The Goldman Sachs GroupLower TargetNeutral$29.00 ➝ $24.00Low
5/10/2019JPMorgan Chase & Co.Lower TargetUnderweight$27.00 ➝ $19.00High
5/10/2019CitigroupDowngradeBuy ➝ Neutral$24.00High
5/10/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$57.00 ➝ $20.00High
4/1/2019JPMorgan Chase & Co.Reiterated RatingSellMedium
3/3/2019JPMorgan Chase & Co.Reiterated RatingSell$27.00Medium
3/1/2019CowenReiterated RatingHold$68.00Low
3/1/2019CitigroupBoost TargetBuy ➝ Buy$67.00 ➝ $70.00Medium
2/28/2019Cantor FitzgeraldReiterated RatingBuy$57.00High
1/17/2019SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$21.00Low
1/3/2019GuggenheimDowngradeBuy ➝ NeutralHigh
12/18/2018Royal Bank of CanadaBoost TargetPositive ➝ Sector Perform$29.00Low
12/18/2018Cantor FitzgeraldBoost Target$55.00High
12/6/2018Royal Bank of CanadaBoost TargetSector Perform$26.00Low
11/19/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$36.00 ➝ $28.00Medium
11/2/2018Bank of AmericaDowngradeBuy ➝ UnderperformHigh
11/2/2018BarclaysDowngradeEqual Weight ➝ Underweight$72.00 ➝ $29.00High
11/2/2018CowenSet TargetHold$68.00High
11/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$83.00 ➝ $23.00High
11/2/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$75.00 ➝ $50.00High
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$75.00Low
9/18/2018CitigroupLower TargetBuy$164.00 ➝ $151.00Medium
9/17/2018GuggenheimInitiated CoverageBuyHigh
9/17/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$42.00High
8/10/2018JPMorgan Chase & Co.Boost TargetOverweight ➝ Buy$80.00 ➝ $83.00High
8/10/2018CowenReiterated RatingHold$80.00High
6/28/2018CitigroupBoost TargetBuy ➝ Buy$146.00 ➝ $164.00Low
5/11/2018Stifel NicolausLower TargetBuy ➝ Buy$95.00 ➝ $87.00Medium
5/7/2018Credit Suisse GroupSet TargetBuy$106.00Medium
4/26/2018Credit Suisse GroupSet TargetBuy$106.00High
4/12/2018BarclaysDowngradeOverweight ➝ Equal Weight$90.00High
3/9/2018Stifel NicolausSet TargetBuy ➝ Buy$85.00 ➝ $95.00Low
3/2/2018Credit Suisse GroupSet TargetBuy$106.00High
3/2/2018BarclaysLower TargetOverweight ➝ Overweight$92.00 ➝ $90.00High
1/24/2018Bank of AmericaLower TargetBuy ➝ Buy$135.00 ➝ $115.00High
1/24/2018CitigroupLower TargetBuy ➝ Buy$164.00 ➝ $146.00High
1/24/2018Credit Suisse GroupLower TargetOutperform ➝ Outperform$147.00 ➝ $106.00High
1/24/2018Royal Bank of CanadaLower TargetSector Perform$77.00High
1/24/2018JPMorgan Chase & Co.Lower TargetOverweight ➝ Buy$138.00 ➝ $91.00High
1/24/2018CowenDowngradeOutperform ➝ Market Perform$123.00 ➝ $68.00High
1/22/2018Credit Suisse GroupSet TargetBuy$142.00 ➝ $147.00Low
1/15/2018Credit Suisse GroupSet TargetBuy$142.00High
1/3/2018CitigroupReiterated RatingBuy$164.00Low
11/10/2017Credit Suisse GroupBoost TargetOutperform$136.00 ➝ $142.00N/A
11/10/2017BarclaysReiterated RatingBuy$103.00 ➝ $122.00N/A
11/10/2017CitigroupBoost TargetBuy ➝ Buy$156.00 ➝ $164.00N/A
11/10/2017Royal Bank of CanadaLower TargetSector Perform$108.00 ➝ $92.00N/A
10/27/2017SVB LeerinkBoost TargetPositive ➝ Outperform$140.00N/A
10/9/2017Bank of AmericaReiterated RatingBuy$117.00 ➝ $135.00N/A
10/5/2017CitigroupReiterated RatingBuy$114.00 ➝ $156.00N/A
10/4/2017JPMorgan Chase & Co.Reiterated RatingBuy$131.00High
10/2/2017Stifel NicolausBoost TargetBuy$110.00 ➝ $130.00Low
(Data available from 10/2/2017 forward)

News Sentiment Rating

-0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/4/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
7/4/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/2/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/2/2022

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Puma Biotechnology logo
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $2.37
Low: $2.28
High: $2.45

50 Day Range

MA: $2.88
Low: $2.27
High: $3.84

52 Week Range

Now: $2.37
Low: $1.60
High: $7.11

Volume

103,685 shs

Average Volume

180,214 shs

Market Capitalization

$107.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Puma Biotechnology?

The following equities research analysts have issued stock ratings on Puma Biotechnology in the last twelve months: HC Wainwright, and StockNews.com.
View the latest analyst ratings for PBYI.

What is the current price target for Puma Biotechnology?

1 Wall Street analysts have set twelve-month price targets for Puma Biotechnology in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 237.6%. HC Wainwright has the highest price target set, predicting PBYI will reach $8.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Puma Biotechnology in the next year.
View the latest price targets for PBYI.

What is the current consensus analyst rating for Puma Biotechnology?

Puma Biotechnology currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PBYI will outperform the market and that investors should add to their positions of Puma Biotechnology.
View the latest ratings for PBYI.

What other companies compete with Puma Biotechnology?

How do I contact Puma Biotechnology's investor relations team?

Puma Biotechnology's physical mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company's listed phone number is (424) 248-6500 and its investor relations email address is [email protected] The official website for Puma Biotechnology is www.pumabiotechnology.com. Learn More about contacing Puma Biotechnology investor relations.